EP4739799A1 - Procédé de diagnostic, de pronostic, de stadification et/ou de traitement in vitro d'une maladie neurodégénérative, d'une maladie neurologique ou d'une maladie liée à l'amyloïde bêta - Google Patents

Procédé de diagnostic, de pronostic, de stadification et/ou de traitement in vitro d'une maladie neurodégénérative, d'une maladie neurologique ou d'une maladie liée à l'amyloïde bêta

Info

Publication number
EP4739799A1
EP4739799A1 EP23741992.4A EP23741992A EP4739799A1 EP 4739799 A1 EP4739799 A1 EP 4739799A1 EP 23741992 A EP23741992 A EP 23741992A EP 4739799 A1 EP4739799 A1 EP 4739799A1
Authority
EP
European Patent Office
Prior art keywords
seq
rna
expression level
predetermined
expression levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23741992.4A
Other languages
German (de)
English (en)
Inventor
Ricardo MAMEDE FIGUEIREDO
Klaus HOFFMEIER
Björn ROTTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genxpro GmbH
Original Assignee
Genxpro GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genxpro GmbH filed Critical Genxpro GmbH
Publication of EP4739799A1 publication Critical patent/EP4739799A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de diagnostic in vitro, de pronostic, de stadification et/ou de suivi du traitement d'une maladie neurodégénérative, d'une maladie neurologique ou d'une maladie liée à l'amyloïde β. L'invention concerne en outre un kit pour mettre en oeuvre le présent procédé.
EP23741992.4A 2023-07-07 2023-07-07 Procédé de diagnostic, de pronostic, de stadification et/ou de traitement in vitro d'une maladie neurodégénérative, d'une maladie neurologique ou d'une maladie liée à l'amyloïde bêta Pending EP4739799A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2023/068898 WO2025011736A1 (fr) 2023-07-07 2023-07-07 Procédé de diagnostic, de pronostic, de stadification et/ou de traitement in vitro d'une maladie neurodégénérative, d'une maladie neurologique ou d'une maladie liée à l'amyloïde bêta

Publications (1)

Publication Number Publication Date
EP4739799A1 true EP4739799A1 (fr) 2026-05-13

Family

ID=87340793

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23741992.4A Pending EP4739799A1 (fr) 2023-07-07 2023-07-07 Procédé de diagnostic, de pronostic, de stadification et/ou de traitement in vitro d'une maladie neurodégénérative, d'une maladie neurologique ou d'une maladie liée à l'amyloïde bêta

Country Status (2)

Country Link
EP (1) EP4739799A1 (fr)
WO (1) WO2025011736A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008025656B4 (de) 2008-05-28 2016-07-28 Genxpro Gmbh Verfahren zur quantitativen Analyse von Nukleinsäuren, Marker dafür und deren Verwendung
EP2733219B1 (fr) 2012-11-16 2017-09-20 Siemens Aktiengesellschaft Marqueurs miRNA de diagnostic pour la maladie d'Alzheimer
EP3083987B1 (fr) 2013-12-19 2020-08-05 Hummingbird Diagnostics GmbH Détermination de plaquettes et de miarn dans la maladie d'alzheimer
ES2734678T3 (es) * 2015-12-22 2019-12-11 Siemens Ag Firmas específicas en enfermedad de alzheimer por perfiles de miarn multicéntricos
JP7398806B2 (ja) 2017-09-05 2023-12-15 アモネタ・ダイアグノスティクス 認知障害の診断用のノンコーディングＲＮＡ（ｎｃＲＮＡ）
WO2019117306A1 (fr) 2017-12-14 2019-06-20 国立大学法人広島大学 Procédé d'assistance à la détection de la maladie d'alzheimer
WO2020018461A1 (fr) * 2018-07-16 2020-01-23 The University Of Virginia Patent Foundation Compositions et méthodes pour le diagnostic et le traitement de maladies neurologiques
CN113286895A (zh) 2018-09-05 2021-08-20 阿莫内塔诊断股份公司 用于诊断和治疗脑疾患，尤其是认知障碍的长的非编码RNA(lncRNA)
WO2020214798A1 (fr) * 2019-04-17 2020-10-22 The Brigham And Women's Hospital, Inc. Signatures épigénétiques de la maladie d'alzheimer
WO2021188825A1 (fr) * 2020-03-18 2021-09-23 Michael Nerenberg Systèmes et procédés de détection d'un risque de maladie d'alzheimer à l'aide d'un dosage de profilage d'arnm sans circulation

Also Published As

Publication number Publication date
WO2025011736A1 (fr) 2025-01-16

Similar Documents

Publication Publication Date Title
US11111541B2 (en) Diagnostic MiRNA markers for Parkinson's disease
US10138520B2 (en) Diagnostic miRNA markers for Alzheimer
US11667974B2 (en) Diagnostic, prognostic and therapeutic uses of long noncoding RNAs for pathologies and toxicities inducing heart disorders
CN113286895A (zh) 用于诊断和治疗脑疾患，尤其是认知障碍的长的非编码RNA(lncRNA)
CN110418850B (zh) 鉴定和使用小rna预测因子的方法
US10457988B2 (en) MiRNAs as diagnostic markers
CN112553328B (zh) 检测基因表达水平的产品及其在制备重度抑郁症诊断工具中的应用
CN106047991A (zh) 用于检测川崎病的方法及试剂盒
US20130178389A1 (en) Composite assay for developmental disorders
US20170130269A1 (en) Diagnosis of neuromyelitis optica vs. multiple sclerosis using mirna biomarkers
KR101828125B1 (ko) 다발성 경화증에서의 진단 miRNA 프로파일
JP2020537514A5 (fr)
US20230203574A1 (en) Blood dna methylation biomarker diagnostic test for anxiety and depressive disorders
CN110387411A (zh) 用于检测狼疮性肾炎或评估狼疮性肾炎风险的方法及其应用
JP2022028438A (ja) アルツハイマー型認知症発症リスク評価のための方法、キット及びデバイス
WO2025011736A1 (fr) Procédé de diagnostic, de pronostic, de stadification et/ou de traitement in vitro d'une maladie neurodégénérative, d'une maladie neurologique ou d'une maladie liée à l'amyloïde bêta
AU2017100960A4 (en) Method of identifying a gene associated with a disease or pathological condition of the disease
WO2025008525A1 (fr) Signature pour le prognostic des récidives de métastases cérébrales
JP2026513264A (ja) ロングリードシーケンシングハイブリッドデータ解析による接合性解析による遠位ゲノム遺伝子座のフェージングのための新規アッセイ
CN107974486A (zh) 一种乳腺癌术后复发风险检测方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR